Company intelligence
Claris Biotherapeutics
Reclaiming Vision, One Eye at a Time
About Claris Biotherapeutics
Claris Bio is a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where no or limited treatment options exist. With an initial focus on limbal stem cell deficiency (LSCD), a blinding disease, we are developing the first pharmacologic treatment with the potential to provide a reliable, accessible, and scalable non-surgical treatment option, while moving medical management beyond today's palliative care and towards meaningful improvements in vision and ocular surface health. Our near-term plan is to advance our lead therapeutic candidate, CSB-001 (oremepermin alpha ophthalmic solution), into LSCD pivotal studies in the first half of 2027, with a longer-term goal to become a leader in developing new therapies that improve vision and change patients’ lives.
Verified activity
Signals from Claris Biotherapeutics
3 published signals
Presence & Recognition
Claris Biotherapeutics team will participate in the Bank of America Healthcare Trailblazers Private Company Showcase Conference on September 24 for additional one-on-one investor meetings.
Reported by Claris Biotherapeutics
Presence & Recognition
Claris Biotherapeutics announced that CEO Stephen Brady will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10.
Reported by Claris Biotherapeutics
Presence & Recognition
Claris Biotherapeutics management team will hold one-on-one meetings with investors during the Wells Fargo 21st Annual Healthcare Conference on September 10.
Reported by Claris Biotherapeutics